Cargando…

Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis

INTRODUCTION: Persistence in drug therapy reflects treatment effectiveness and tolerability. We aim to estimate the persistence of apremilast prescribed to patients with psoriatic arthritis (PsA) and to identify characteristics associated with treatment discontinuation in a real-world setting. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haddad, Amir, Stein, Nili, Lavi, Idit, Shynkar, Lisa, Bergman, Irina, Feldhamer, Ilan, Cohen, Arnon Dov, Saliba, Walid, Zisman, Devy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560465/ https://www.ncbi.nlm.nih.gov/pubmed/37814674 http://dx.doi.org/10.2147/BTT.S425693

Ejemplares similares

Treatment persistence of biologics among patients with psoriatic arthritis
por: Haddad, Amir, et al.
Publicado: (2021)

The association between psoriatic arthritis and venous thromboembolism: a population-based cohort study
por: Gazitt, Tal, et al.
Publicado: (2022)

The epidemiology of psoriatic arthritis in Israel – a population-based study
por: Eder, Lihi, et al.
Publicado: (2018)

Implementation of the Treat-to-Target Concept in Evaluation of Psoriatic Arthritis Patients
por: Gazitt, Tal, et al.
Publicado: (2021)

Comorbidities in Patients with Psoriatic Arthritis
por: Haddad, Amir, et al.
Publicado: (2017)

High Dimensional Analyses of Circulating Immune Cells in Psoriatic Arthritis Detects Elevated Phosphorylated STAT3
por: Macaubas, Claudia, et al.
Publicado: (2022)

Clinical potential of apremilast in the treatment of psoriatic arthritis
por: Cauli, Alberto, et al.
Publicado: (2014)

Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
por: Forchhammer, Stephan, et al.
Publicado: (2015)

The role of EMMPRIN/CD147 in regulating angiogenesis in patients with psoriatic arthritis
por: Rahat, Michal A., et al.
Publicado: (2020)

Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population
por: Berman, Julia, et al.
Publicado: (2021)

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2014)

Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: an analytical cohort study
por: Hassan, Shadi, et al.
Publicado: (2016)

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast
por: Palfreeman, Andrew C, et al.
Publicado: (2013)

Erratum to: Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2015)

The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis
por: Liu, Yong, et al.
Publicado: (2014)

Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic
por: Das, Ashis K., et al.
Publicado: (2023)

Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report
por: Gualtierotti, Roberta, et al.
Publicado: (2019)

Correction: Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic
por: Das, Ashis K., et al.
Publicado: (2023)

Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease—results of the Immune Metabolic Associations in Psoriatic Arthritis study
por: Ferguson, Lyn D, et al.
Publicado: (2021)

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
por: Mease, Philip J., et al.
Publicado: (2020)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
por: Gladman, Dafna D., et al.
Publicado: (2020)

Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature
por: Garcovich, Simone, et al.
Publicado: (2020)

Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink
por: Persson, Rebecca, et al.
Publicado: (2022)

Successful treatment with secukinumab in an HIV‐positive psoriatic patient after failure of apremilast
por: Romita, Paolo, et al.
Publicado: (2022)

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial
por: Wells, Alvin F, et al.
Publicado: (2018)

Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study
por: Becciolini, Andrea, et al.
Publicado: (2023)

Predictors and Long-Term Prognostic Significance of Acute Renal Function Change in Patients Who Underwent Surgical Aortic Valve Replacement
por: Leviner, Dror B., et al.
Publicado: (2023)

Delayed Colonoscopy Following a Positive Fecal Test Result and Cancer Mortality
por: Flugelman, Anath A, et al.
Publicado: (2019)

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
por: Kavanaugh, Arthur, et al.
Publicado: (2014)

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies
por: Gladman, Dafna D, et al.
Publicado: (2018)

Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis
por: Kawalec, P., et al.
Publicado: (2017)

Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective
por: Purmonen, Timo, et al.
Publicado: (2018)

Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis
por: Hagberg, Katrina Wilcox, et al.
Publicado: (2020)

Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study
por: de Vlam, Kurt, et al.
Publicado: (2022)

Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study
por: Pina Vegas, Laura, et al.
Publicado: (2021)

The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast
por: Arias de la Rosa, Ivan, et al.
Publicado: (2022)

Comparison between methotrexate and apremilast in Psoriatic Arthritis-a single blind randomized controlled trial (APREMEPsA study)
por: Samanta, Joydeep, et al.
Publicado: (2023)

Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
por: Mease, Philip J., et al.
Publicado: (2023)

The effect of Apremilast on signal transduction and IL-10 production in CD39high regulatory B cells in patients with psoriatic arthritis
por: Sakkas, Lazaros I., et al.
Publicado: (2018)

Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study
por: Suruki, Robert Y, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2qjv3rnj436lsrh6ls8kqp5hq5